Faculty Bibliography

PURPOSE: To evaluate the relationship between mammographic breast density (MBD), background parenchymal enhancement (BPE), and fibroglandular tissue (FGT) in women with breast cancer (BC) and at high risk for developing BC. METHODS: Our institutional database was queried for patients who underwent mammography and MRI. RESULTS: Four hundred three (85%) had BC and 72 (15%) were at high risk. MBD (P=.0005), BPE (P<.0001), and FGT (P=.02) were all higher in high-risk women compared to the BC group. CONCLUSIONS: Higher levels of MBD, BPE and FGT are seen in women at higher risk for developing BC when compared to women with BC.

Objective Sentinel lymph node biopsy (SLNB) is a widely accepted and safe technique that increases the accuracy of axillary staging in breast cancer for patients with clinically node-negative disease. Results from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial found no benefit for completion axillary lymph node dissection (ALND) in patients with breast cancer involving 1 to 2 positive sentinel nodes. The purpose of our study was to characterize the population of patients who had ALND since the publication of the Z0011 results. Methods This was an IRB-approved retrospective review of women with newly diagnosed breast cancer between 1/2010 and 6/2013 who were clinically node-negative and had >1 positive sentinel lymph node (SLN). Variables of interest included age, method of presentation, body mass index (BMI), tumor characteristics, surgery type, and preop imaging. Patients who received neoadjuvant therapy were excluded. Descriptive statistics and Pearson's chisquare analyses were utilized. Results Out of a total of 1,513 patients, 191 (12%) patients had >1 positive SLN in their initial surgery. The mean age was 56 years. Of the patients with a positive SLN, 139 (73%) went on to have a completion ALND. The distribution of age and tumor type was similar in patients who had SLNB alone and who underwent completion ALND. However, a higher proportion of patients who underwent completion ALND had later stage disease (p < 0.0001), larger tumors (p = 0.012), and greater number of positive SLN (p = 0.004), and had a higher BMI (p = 0.05). Among the 139 patients who went on to have a complete ALND, 127 (91%) patients had frozen section analysis with > 1 positive lymph node. Of these patients, 72 (57%) had 1 lymph node positive for metastasis and 41 (32%) had 2 lymph nodes positive for metastasis on final pathology. Conclusion Our study showed that women who had a completion ALND presented with later stage disease, larger tumors, and greater number of positive SLN. Frozen section analysis at the time of SLNB led to ALND in 113 patients with 1 or 2 positive SLN on final pathology. These patients would not meet the criteria for axillary dissection based on the results of Z0011. This suggests that patients should either undergo completion axillary dissection if 3 or more lymph nodes are found to have metastatic disease on frozen section or that completion dissection should be deferred until final pathology confirms the presence of 3 or more positive lymph nodes

Background: Current methods for intraoperative assessment of lumpectomy margins are limited, and a meaningful proportion of patients require re-excision to achieve acceptable margins. There is little available information regarding the relationship of mammographic breast density (BD) and positive margin rate. Methods: The MarginProbe device uses radiofrequency spectroscopy to evaluate the margins of lumpectomy specimens. The current study utilized data from the MarginProbe Pivotal Trial (Dune Medical Devices, Israel, NCT00749931 ). This randomized clinical trial compared adjunctive intraoperative use of the MarginProbe device with surgeons' standard approach to lumpectomy surgery. For the current analysis, data was compiled from the period prior to patient randomization and device use. Variables of interest included BD, patient and tumor characteristics, and the margin status of the main lumpectomy specimen (prior to device use in the device arm). For the purpose of this analysis, a positive margin was considered tumor on ink. Statistical analysis was performed with univariate and multivariate analysis, and linear/logistic regression. Results: A total of 664 patients were enrolled in the trial. 450 patients had preoperative breast density information available, and formed the basis for this analysis. As expected, higher BD was associated with younger age, lower BMI and smaller breast and specimen volume. Increased BD was also associated with increased use of preoperative MRI imaging (odds ratio 2.2, p<0.0001). Higher BD was also associated with a significant increase in main lumpectomy specimen positive margin rate (Table). The odds ratio was 1.46 per change in density category (p=0.011). BD remained significantly associated with positive margins after controlling for age, BMI and breast volume. Conclusions: Higher BD is an independent risk factor for positive margins in main lumpectomy specimens, suggesting that adjunctive methods for intraoperative margin assessment may be particularly helpful in these patients. (table present)

With the completion of the Human Genome Project and the development of high throughput technologies, such as next-generation sequencing, the use of multiplex genetic testing, in which multiple genes are sequenced simultaneously to test for one or more conditions, is growing rapidly. Reflecting underlying heterogeneity where a broad range of genes confer risks for one or more cancers, the development of genetic cancer panels to assess these risks represents just one example of how multiplex testing is being applied clinically. There are a number of issues and challenges to consider when conducting genetic testing for cancer risk assessment, and these issues become exceedingly more complex when moving from the traditional single-gene approach to panel testing. Here, we address the practical considerations for clinical use of panel testing for breast, ovarian, and colon cancers, including the benefits, limitations and challenges, genetic counseling issues, and management guidelines.